## Explanatory Statement

**EXPLANATORY STATEMENT**

*Food Standards Australia New Zealand Act 1991*

***F******ood Standards (Application A1284 – Triacylglycerol lipase from GM* Trichoderma reesei *as a processing aid) Variation***

**1. Authority**

Section 13 of the *Food Standards Australia New Zealand Act 1991* (the FSANZ Act) provides that the functions of Food Standards Australia New Zealand (the Authority) include the development of standards and variations of standards for inclusion in the *Australia New Zealand Food Standards Code* (the Code).

Division 1 of Part 3 of the FSANZ Act specifies that the Authority may accept applications for the development or variation of food regulatory measures, including standards. This Division also stipulates the procedure for considering an application for the development or variation of food regulatory measures.

The Authority accepted Application A1284 which sought to amend the Code to permit the use of a protein engineered variant of the enzyme triacylglycerol lipase (EC 3.1.1.3) from a genetically modified *Trichoderma reesei* containing a triacylglycerol lipase gene from *Thermomyces lanuginosu*s as a processing aid in the manufacture of bakery and other cereal-based products. The Authority considered the application in accordance with Division 1 of Part 3 and has approved a draft variation: the *Food Standards (Application A1284 – Triacylglycerol lipase from GM* Trichoderma reesei *as a processing aid) Variation* (the approved draft variation)*.*

Following consideration by the Food Ministers’ Meeting (FMM), section 92 of the FSANZ Act stipulates that the Authority must publish a notice about the draft variation.

**2. Variation is a legislative instrument**

The approved draft variation is a legislative instrument for the purposes of the *Legislation Act 2003* (see section 94 of the FSANZ Act) and is publicly available on the Federal Register of Legislation (www.legislation.gov.au).

This instrument is not subject to the disallowance or sunsetting provisions of the *Legislation Act 2003.* Subsections44(1) and 54(1) of that Actprovide that a legislative instrument is not disallowable or subject to sunsetting if the enabling legislation for the instrument (in this case, the FSANZ Act): (a) facilitates the establishment or operation of an intergovernmental scheme involving the Commonwealth and one or more States; and (b) authorises the instrument to be made for the purposes of the scheme. Regulation 11 of the *Legislation (Exemptions and other Matters) Regulation 2015* also exempts from sunsetting legislative instruments a primary purpose of which is to give effect to an international obligation of Australia.

The FSANZ Actgives effect to an intergovernmental agreement (the Food Regulation Agreement) and facilitates the establishment or operation of an intergovernmental scheme (national uniform food regulation). That Act alsogives effect to Australia’s obligations under an international agreement between Australia and New Zealand. For these purposes, the Act establishes the Authority to develop food standards for consideration and endorsement by the FMM. The FMM is established under the Food Regulation Agreement and the international agreement between Australia and New Zealand, and consists of New Zealand, Commonwealth and State/Territory members. If endorsed by the FMM, the food standards on gazettal and registration are incorporated into and become part of Commonwealth, State and Territory and New Zealand food laws.

These standards or instruments are then administered, applied, and enforced by these jurisdictions’ regulators as part of those food laws.

**3. Purpose**

The Authority has approved a draft variation amending the table to subsection S18––9(3) of the Code to permit the use of a protein engineered variant of the enzyme triacylglycerol lipase (EC 3.1.1.3) from a genetically modified *Trichoderma reesei* containing a gene from *Thermomyces lanuginosus* as a processing aid in the manufacture of bakery and other cereal-based products.

This permission is subject to the condition that the maximum permitted level or amount of the enzyme that may be present in the food must be consistent with good manufacturing practice (GMP).

**4. Documents incorporated by reference**

The approved draft variation does not incorporate any documents by reference.

However, existing provisions of the Code incorporate documents by reference that would prescribe identity and purity specifications for the processing aid to be permitted by the approved draft variation. Section 1.1.1—15 of the Code requires substances used as processing aids to comply with any relevant identity and purity specifications listed in Schedule 3 of the Code. Section S3—2 of Schedule 3 incorporates by reference the specifications listed in the Joint FAO/WHO Expert Committee on Food Additives (JECFA) Compendium of Food Additive Specifications (FAO/WHO 2021) and the United States Pharmacopeial Convention (2022) Food Chemicals Codex (13th edition). These include general specifications for the identity and purity parameters of enzyme preparations used in food processing.

**5. Consultation**

In accordance with the procedure in Division 1 of Part 3 of the FSANZ Act, the Authority’s consideration of Application A1284 included one round of public consultation following an assessment, and the preparation of a draft variation to the Code and associated assessment summary. FSANZ called for submissions on the draft variation from 6 March to 17 April 2024.

Changes have been made to the Impact Analysis requirements by the Office of Impact Analysis (OIA)[[1]](#footnote-1). Impact analysis is no longer required to be finalised with the OIA. Prior to these changes, the OIA advised FSANZ that a Regulatory Impact Statement (RIS) was not needed for applications relating to processing aids and genetically modified food. This is because applications relating to permitting the use of processing aids and genetically modified food that have been determined to be safe are minor and deregulatory in nature, as their use will be voluntary if the draft variation concerned is approved.

Under this approach, FSANZ’s assessment is that a RIS is not needed for this application.

**6. Statement of compatibility with human rights**

This instrument is exempt from the requirements for a statement of compatibility with human rights as it is a non-disallowable instrument under section 44 of the *Legislation Act 2003*.

**7. Variation**

References to ‘the variation’ in this section are references to the approved draft variation.

Clause 1 provides that the name of the variation is the *Food Standards (Application A1284 – Triacylglycerol lipase from GM* Trichoderma reesei *as a processing aid) Variation*.

Clause 2 provides that the Code is amended by the Schedule to the variation.

Clause 3 provides that the variation commences on the date of gazettal of the instrument.

***Schedule to the variation***

**Item [1]** of the Schedule to the variation inserts a new entry, in alphabetical order, into column 1 of the table to subsection S18—9(3) of the Code.

The new entry consists of the following enzyme:

‘Lipase, triacylglycerol, protein engineered variant, (EC 3.1.1.3) sourced from *Trichoderma reesei* containing the lipase, triacylglycerol gene from *Thermomyces lanuginosus*.’

The permitted technological purpose for this enzyme is prescribed in column 2 of the table. The prescribed purpose is ‘For use in the manufacture of bakery and other cereal-based products’.

The permission is subject to the condition, as prescribed in column 3 of the table, that the maximum permitted level or amount of this enzyme that may be present in the food must be consistent with GMP.

The effect of item [1] is to permit the proposed use of the protein engineered variant of the enzyme triacylglycerol lipase (EC 3.1.1.3) sourced from a GM *Trichoderma reesei* containing the lipase, triacylglycerol gene from *Thermomyces lanuginosus* as a processing aidin accordance with the Code.

**Item [2]** of the Schedule to the variation amends the dot point list of protein engineered variants of enzymes in the note after the table to subsection S18—9(3).

That note relates to protein engineered variants of enzymes, which are listed in the table to subsection S18—9(3) as processing aids permitted to be used for specific technological purposes. The note explains that if such an enzyme is used as a processing aid, the resulting food may have as an ingredient a food produced using gene technology, and the requirements relating to foods produced using gene technology in the Code will apply (see Standard 1.2.1 and Standard 1.5.2). The note then lists the relevant substances.

Item [2] omits the dot point list of protein engineered variants of enzymes in the note after the table to subsection S18—9(3), and substitutes with the following list:

* Cellulase, protein engineered variant;
* Endo-1,4-ß-xylanase, protein engineered variant;
* Fructan β-fructosidase, protein engineered variant;
* Glucoamylase, protein engineered variant;
* Lipase, triacylglycerol, protein engineered variant;
* Maltogenic α-amylase, protein engineered variant;
* Protein engineered enzymes used in the manufacture of various steviol glycosides;
* Subtilisin, protein engineered variant.

The effect of the amendment in item [2] is to include a reference to this protein engineered variant of triacylglycerol lipase in that list, in alphabetical order.

1. Regulatory Impact Analysis Guide for Ministers’ Meetings and National Standard Setting Bodies | The Office of Impact Analysis (pmc.gov.au) [↑](#footnote-ref-1)